[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fa8LGyUX1xPlTCcfoPYn_EXCcvQQgnn_5LMKGm6JqzBw":8,"$fGqKykMXaGS9u3XOR-H0m5SeGKH7jaPdIMBDDuXkgPDI":56,"$fmwthRMO6v0lapDgfxwBsWiRTdmOEaQ7m_Vs8qn2zbys":60},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":55},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":28,"isThumbsUp":7,"isCollection":7,"collections":28,"createTime":29,"seoTitle":22,"seoKeywords":30,"seoDescription":31,"shelvesTime":32,"version":33,"menus":34,"menuId":36,"type":43,"quality":54,"commentCount":28,"isComment":43},67686,869632,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//JmQqBzPAeSw5dIlxYvXzvSvx1na6xI56.png","李有委","新乡医学院第一附属医院","普外科","主治医师",21,8,"乳腺癌治疗的新视角：聚焦pT2N0Mx HER2阳性患者的用药指南","","https://ystcdn.venuertc.com/venue/AI/83e0c18f-eace-46e9-86db-34533cb3eebf.jpg","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌治疗的新视角：聚焦pT2N0Mx HER2阳性患者的用药指南\u003C/h2>\n  \u003Cp class=\"drug-guide-intro\">\n    大家对乳腺癌治疗中用药方案的重视度越来越高，尤其是针对HER2阳性的分型。其实，药品管理和使用远不止记住药名那么简单。本文会梳理关于pT2N0Mx HER2阳性乳腺癌治疗相关药品的七个关键细节，包括药物成分、用法、相互作用、不良反应及储存方法等，希望每位患者和家属都能记住这些用药重点，让治疗更安全、更有效。👩‍⚕️\n  \u003C/p>\n\u003C/div>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f7f9fb 0%, #e5ebf6 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品基础信息及常用成分\u003C/h2>\n    \u003Cp>\n      在乳腺癌pT2N0Mx HER2阳性治疗过程中，最常用的药物类型包括化疗药物（如紫杉醇、表柔比星和环磷酰胺）、靶向药物（如曲妥珠单抗、帕妥珠单抗）以及辅助药物（止吐药、护肝药等）。\u003Cbr>\n      \u003C/p>\u003Cul>\n        \u003Cli>紫杉醇（Paclitaxel）：常见剂型为注射液，包装规格多为30mg/5ml或100mg/16.7ml。\u003C/li>\n        \u003Cli>表柔比星（Epirubicin）：一般为注射剂，含量多见于50mg/25ml。\u003C/li>\n        \u003Cli>曲妥珠单抗（Trastuzumab）：为静脉注射粉剂或预配液，规格如440mg/20ml。\u003C/li>\n      \u003C/ul>\n      靶向药物通过干扰HER2蛋白的信号传导途径，辅助药物则用于减轻化疗带来的不适反应。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f1f6f2 0%, #eaf3ec 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药理作用原理解析✨\u003C/h2>\n    \u003Cp>\n      各类药物的核心作用机制如下：\n      \u003C/p>\u003Cul>\n        \u003Cli>\n          紫杉醇：干扰微管结构，阻止细胞分裂（参考：Wani MC et al., \"Plant antitumor agents. III. The isolation and structure of taxol, an antileukemic and antitumor agent from Taxus brevifolia\", J Am Chem Soc, 1971）。\n        \u003C/li>\n        \u003Cli>\n          表柔比星：通过抑制DNA合成，导致细胞死亡。\n        \u003C/li>\n        \u003Cli>\n          曲妥珠单抗：特异性结合HER2受体，阻断信号通路，影响细胞增殖（参考：Baselga J et al., \"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor effects of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts\", Cancer Res, 1998）。\n        \u003C/li>\n      \u003C/ul>\n      辅助用药（如止吐药）则通过阻断中枢或外周受体来控制化疗相关的不适。\n      \u003Cbr>正确做法：了解每种药物的基本作用，有助于配合医生选择最佳治疗方案。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #fbf7f5 0%, #ede1db 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用法用量及具体服用细节💊\u003C/h2>\n    \u003Cp>\n      药品的正确使用方式直接决定疗效和安全性——\n      \u003C/p>\u003Cul>\n        \u003Cli>静脉注射化疗药物（如紫杉醇、表柔比星）：严格按疗程和剂量，通常每3周一次，由专业医护人员操作。\u003C/li>\n        \u003Cli>曲妥珠单抗：首次给药剂量较高（例：8mg/kg），维持剂量（例：6mg/kg），间隔21天一次静脉滴注；实际剂量由医生根据体重和疗程调整。\u003C/li>\n        \u003Cli>止吐药、保肝药：配合主药短期口服或注射，遵医嘱定时定量即可。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drug-guide-case\">临床上使用紫杉醇时，护士需先做皮试，监测过敏反应，之后静脉点滴，确保用药安全。\u003C/span>\n      \u003Cbr>\n      正确做法：绝对不能自行调整化疗或靶向药物的剂量和频率，如有疑问，要及时向医生咨询。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f7faf7 0%, #e2f6eb 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用重点提醒⚠️\u003C/h2>\n    \u003Cp>\n      部分药品间可能出现显著相互作用，需要格外小心：\n      \u003C/p>\u003Cul>\n        \u003Cli>\n          曲妥珠单抗与顺铂类药物合用时，应监测肾功能，因为顺铂有潜在肾毒性。\n        \u003C/li>\n        \u003Cli>\n          紫杉醇遇到苯妥英钠（Phenytoin）等抗癫痫药物可能加剧神经毒性。\n        \u003C/li>\n        \u003Cli>\n          辅助药如止吐药（昂丹司琼、格拉司琼）与部分抗抑郁药合用可能增加心律失常患风险（参考：Vial T et al., \"Risk of cardiac arrhythmia associated with antiemetics\", Drug Safety, 2012）。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drug-guide-case\">有位患者在曲妥珠单抗基础上同时服用左乙拉西坦，经过药师研讨后，调整了服药时间以避免相互影响。\u003C/span>\n      \u003Cbr>\n      正确做法：所有药品务必提前告知医生，尤其是正在用的降压、抗病毒、抗抑郁类药物。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f5fafe 0%, #dce5ee 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 特殊人群用药调整 & 用药案例💡\u003C/h2>\n    \u003Cp>\n      用药安全性在特殊人群尤为关键——\n      \u003C/p>\u003Cul>\n        \u003Cli>\n          老年患者：由于肝肾功能减退，曲妥珠单抗及化疗药物需要评估肝肾指标后酌情减量。\n        \u003C/li>\n        \u003Cli>\n          孕妇及哺乳期妇女：化疗及大部分靶向药物（如曲妥珠单抗）目前未证实安全，建议暂缓使用或换用其他方案。\n        \u003C/li>\n        \u003Cli>\n          肝肾功能不全者：需严格监测肝肾功能并及时调整方案，必要时停药。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drug-guide-case\">一位肝功轻度异常的患者使用紫杉醇期间，医生加密肝功能检测并调整剂量，成功避免了不良反应。\u003C/span>\n      \u003Cbr>\n      正确做法：用药前如有特殊情况（孕期、肝肾疾病），必须如实告知医师，不可自行决定改药或停药。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #fcf6f7 0%, #f9e5ed 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应与处理策略🚩\u003C/h2>\n    \u003Cp>\n      每种药物都有可能出现不良反应，及时识别和应对至关重要——\n      \u003C/p>\u003Cul>\n        \u003Cli>\n          化疗药物（紫杉醇、表柔比星）：可能导致脱发、口腔溃疡、神经毒性、骨髓抑制。数据显示，紫杉醇相关中性粒细胞减少发生率可达30%。出现这些反应时，需及时监测血常规并对症处理。\n        \u003C/li>\n        \u003Cli>\n          曲妥珠单抗：约2%-4%患者可能出现心脏相关副作用（左室射血分数损失），此时应立即停止用药并评估。\n        \u003C/li>\n        \u003Cli>\n          辅助药（止吐药等）：偶发头晕、心悸、轻微过敏反应，处理方法为停药或换药，严重者需紧急就医。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"drug-guide-case\">患者第七周期紫杉醇输注后，未出现恶心呕吐，相比说明书统计不良反应发生率明显降低。\u003C/span>\n      \u003Cbr>\n      正确做法：感觉不适时，第一时间联系医护人员，不要自行加药或停药。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f5fcf4 0%, #daf3e7 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 药品储存、有效期与过量处理🕰️\u003C/h2>\n    \u003Cp>\n      药品保存与过量处理同样关系到安全——\n      \u003C/p>\u003Cul>\n        \u003Cli>\n          紫杉醇、表柔比星、曲妥珠单抗注射液应储存于2-8℃冰箱内，避免阳光直射；开瓶后24小时内用完。\n        \u003C/li>\n        \u003Cli>\n          辅助口服药（止吐药）：室温储存（15-25℃），避光、干燥密闭保存，过期或变色需丢弃，不可继续服用。\n        \u003C/li>\n        \u003Cli>\n          一旦误服过量或重复给药，须立即暂停用药，迅速联系医生或前往急诊处理，不推荐自行催吐或用其他药物抵消。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cbr>\n      正确做法：核查药盒标签，定期清理家中药品，严格按照药师指导储存和使用每一种药物。患者家属如果发现漏服或多服，不可轻视，应及时沟通医生，切勿随意补药或断药。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f5f9fc 0%, #e6f2f2 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 综合用药方案管理🏷️\u003C/h2>\n    \u003Cp>\n      药品管理不仅是患者个人行为，也是家庭与医护配合的责任：\n      \u003C/p>\u003Cul>\n        \u003Cli>\n          \u003Cb>用药记录习惯：\u003C/b>建议每周期使用日历或APP跟踪化疗、靶向药物及辅助药物的使用时间、剂量、批次；记录每次是否漏服。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>监测体征与实验室指标：\u003C/b>每周抽查血常规、肝肾功能，发现异常及时调整用药。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>遵医嘱复查：\u003C/b>例：3周后返院继续化疗，及时预约检查，康复锻炼要配合。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>药品咨询渠道：\u003C/b>遇到用药相关问题，可向专业药师或咨询平台寻求帮助，切勿相信网络传言和偏方。\n        \u003C/li>\n      \u003C/ul>\n      其实，用药管理就像日常财务记账，养成按时、准确、规范的习惯，能大大减低用药风险，也有助于药品疗效最大化。\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f6f6fc 0%, #e3e3fb 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 数据解读与权威参考📊\u003C/h2>\n    \u003Cp>\n      数据显示，HER2阳性乳腺癌患者在曲妥珠单抗联合化疗方案下，三年生存率提升约25%（参考：Slamon DJ et al., \"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2\", New England J Med, 2001）。不过，心脏副作用及骨髓抑制风险需重视并随时观察。\n      使用紫杉醇时，中性粒细胞减少症发生率约30%-40%，而曲妥珠单抗心脏相关副作用发生率为2%-4%。这些数据支持我们对药品风险的科学管理。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-guide-section\">\n  \u003Cdiv class=\"drug-guide-section-bg\" style=\"background-image: linear-gradient(90deg, #f6fcf6 0%, #dff4e3 100%)\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 总结与行动指南📑\u003C/h2>\n    \u003Cp>\n      总结下来，乳腺癌pT2N0Mx HER2阳性用药方案涉及多个药品，安全使用的关键在于严格遵守剂量、时间、储存、告知所有当前用药情况，并及时识别和应对不良反应。\u003Cbr>\n      \u003C/p>\u003Cul>\n        \u003Cli>最重要的注意事项是绝不能自行调整化疗或靶向药物用量。\u003C/li>\n        \u003Cli>及时报告所有药品合用情况，避免相互作用风险。\u003C/li>\n      \u003C/ul>\n      鼓励所有使用相关药品的患者及家属，积极沟通医师和药师，持续学习用药知识，用药安全就是最大保障。如果对药品有任何疑问，第一选择是专业咨询，而不是寻求民间偏方或自行决策。治疗的路上，正确用药才是最好的“护身符”。🌱\n    \u003Cp>\u003C/p>\n    \u003Cdiv class=\"drug-guide-references\">\n      \u003Ch3 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h3>\n      \u003Cul>\n        \u003Cli>Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971). Plant antitumor agents. III. The isolation and structure of taxol, an antileukemic and antitumor agent from Taxus brevifolia. \u003Ci>Journal of the American Chemical Society\u003C/i>, 93(9), 2325–2327.\u003C/li>\n        \u003Cli>Baselga, J., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. (1998). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor effects of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. \u003Ci>Cancer Research\u003C/i>, 58(13), 2825–2831.\u003C/li>\n        \u003Cli>Vial, T., Sall L., Vannier B., et al. (2012). Risk of cardiac arrhythmia associated with antiemetics. \u003Ci>Drug Safety\u003C/i>, 35(7), 599–612.\u003C/li>\n        \u003Cli>Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. \u003Ci>New England Journal of Medicine\u003C/i>, 344(11), 783–792.\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Cstyle>\n.drug-guide-title {\n  padding: 32px 48px;\n  background: linear-gradient(90deg, #f2fbfc 0%, #e7eaf7 100%);\n  border-radius: 12px;\n  margin-bottom: 32px;\n  box-shadow: 0 2px 8px rgba(60, 88, 109, 0.04);\n}\n.drug-guide-intro {\n  font-size: 20px;\n  color: #30405e;\n  margin-top: 18px;\n  line-height: 1.6;\n}\n.drug-guide-section {\n  margin-bottom: 40px;\n  max-width: 900px;\n  margin-left: auto;\n  margin-right: auto;\n}\n.drug-guide-section-bg {\n  border-radius: 14px;\n  padding: 38px 46px;\n  box-shadow: 0 1px 7px rgba(153, 183, 221, 0.09);\n  background-repeat: no-repeat;\n  background-size: cover;\n}\n.drug-guide-section h2 {\n  color: #163173;\n  font-size: 27px;\n  font-weight: 600;\n  margin-bottom: 20px;\n  padding-left: 6px;\n}\n.drug-guide-section p,\n.drug-guide-section ul {\n  font-size: 18px;\n  color: #345061;\n  line-height: 1.72;\n  margin-bottom: 0;\n  margin-top: 0;\n}\n.drug-guide-section ul {\n  padding-left: 22px;\n  margin-top: 14px;\n  margin-bottom: 14px;\n}\n.drug-guide-section li {\n  margin-bottom: 10px;\n}\n\n.drug-guide-case {\n  display: block;\n  background: #f0f6fd;\n  border-left: 5px solid #9abefa;\n  margin: 20px 0 12px 0;\n  padding: 14px 20px;\n  font-size: 16px;\n  color: #456199;\n  border-radius: 6px;\n  font-style: italic;\n}\n\n.drug-guide-references {\n  margin-top: 30px;\n  margin-left: 8px;\n  margin-bottom: 2px;\n}\n.drug-guide-references h3 {\n  font-size: 20px;\n  color: #51418e;\n  margin-bottom: 14px;\n  font-weight: 700;\n}\n.drug-guide-references ul {\n  font-size: 16px;\n  color: #312c45;\n  line-height: 1.5;\n  padding-left: 20px;\n}\n.drug-guide-references li {\n  margin-bottom: 12px;\n}\n\n@media (max-width: 800px) {\n  .drug-guide-title,\n  .drug-guide-section-bg {\n    padding: 20px 12px;\n  }\n  .drug-guide-section h2 {\n    font-size: 22px;\n  }\n  .drug-guide-section p,\n  .drug-guide-section ul {\n    font-size: 16px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2e",525,0,"2025-10-11 14:31:58","乳腺癌, HER2阳性, 用药指南, 化疗药物, 靶向药物, 不良反应, 药物相互作用, 用药安全","专为pT2N0Mx HER2阳性乳腺癌患者设计的药物指南，highlight关键药物作用，使用细节及不良反应应对，帮助患者及家属安全用药，提升治疗效果。","2025-10-28 12:00:00",2,[35],{"menuId":36,"menuName":37,"parentId":28,"orderNum":33,"path":38,"component":39,"isFrame":40,"isCache":41,"menuType":42,"visible":43,"status":28,"createDept":6,"remark":23,"createTime":44,"children":45,"columnImage":46,"columnLogo":47,"uncheckedLogo":6,"checkedLogo":6,"isHot":43,"isHome":28,"forceLogin":28,"color":48,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":38,"componentInfo":39},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":57,"success":55},{"pageNo":43,"pageSize":58,"result":59,"totalSize":28},10,[],{"code":9,"msg":10,"message":6,"data":61,"success":55},{"authors":62,"appraiseDimensionScoresVos":63},[],[]]